Literature DB >> 21771891

Absence of the glucagon-like peptide-1 receptor does not affect the metabolic phenotype of mice with liver-specific G(s)α deficiency.

Min Chen1, Eralda Mema, James Kelleher, Nicholas Nemechek, Alta Berger, Jie Wang, Tao Xie, Oksana Gavrilova, Daniel J Drucker, Lee S Weinstein.   

Abstract

The stimulatory G protein α-subunit (G(s)α) couples hormone and other receptors to the generation of intracellular cAMP. We previously showed that mice with liver-specific G(s)α deficiency [liver-specific G(s)α knockout (LGsKO) mice] had reduced adiposity and improved glucose tolerance associated with increased glucose-stimulated insulin secretion, pancreatic islet hyperplasia, and very high serum glucagon and glucagon-like peptide 1 (GLP-1) levels. Because GLP-1 is known to stimulate insulin secretion and to have effects on energy balance, we mated LGsKO mice with germline GLP-1 receptor (GLP-1R) knockout mice (Glp1r(-/-)) and compared LGsKO to double-knockout (LGs/Glp1r(-/-)) mice to determine the contribution of excess GLP-1R signaling to the LGsKO phenotype. Loss of the GLP-1R failed to reverse most of the metabolic features of LGsKO mice, including reduced fat mass, increased glucose tolerance, and second-phase glucose-stimulated insulin secretion, islet cell hyperplasia, and very high glucagon and GLP-1 levels. However, loss of GLP-1R impaired first-phase insulin secretion in mice with or without liver-specific G(s)α deficiency. Thus, excess GLP-1 action (or at least through GLP-1R) does not contribute to the LGsKO metabolic phenotype, and other unknown factors involved in the cross talk between the liver G(s)α/cAMP pathway and pancreatic islet function need to be further elucidated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21771891      PMCID: PMC3159780          DOI: 10.1210/en.2011-0012

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  32 in total

1.  Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.

Authors:  Kyle W Sloop; Julia Xiao-Chun Cao; Angela M Siesky; Hong Yan Zhang; Diane M Bodenmiller; Amy L Cox; Steven J Jacobs; Julie S Moyers; Rebecca A Owens; Aaron D Showalter; Martin B Brenner; Achim Raap; Jesper Gromada; Brian R Berridge; David K B Monteith; Niels Porksen; Robert A McKay; Brett P Monia; Sanjay Bhanot; Lynnetta M Watts; M Dodson Michael
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

2.  Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells.

Authors:  H C Fehmann; J F Habener
Journal:  Endocrinology       Date:  1992-01       Impact factor: 4.736

3.  Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.

Authors:  S Mojsov; G C Weir; J F Habener
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

4.  Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

Authors:  D J Drucker; J Philippe; S Mojsov; W L Chick; J F Habener
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

5.  GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.

Authors:  Eva Tomas; Jenna A Wood; Violeta Stanojevic; Joel F Habener
Journal:  Regul Pept       Date:  2011-05-04

6.  Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus.

Authors:  G M Reaven; Y D Chen; A Golay; A L Swislocki; J B Jaspan
Journal:  J Clin Endocrinol Metab       Date:  1987-01       Impact factor: 5.958

7.  Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein.

Authors:  Xiao Yan Zhou; Nobuyuki Shibusawa; Karuna Naik; Delia Porras; Karla Temple; Hesheng Ou; Kelly Kaihara; Michael W Roe; Matthew J Brady; Fredric E Wondisford
Journal:  Nat Med       Date:  2004-05-16       Impact factor: 53.440

8.  Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

Authors:  B Thorens
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

9.  Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction.

Authors:  Pere Puigserver; James Rhee; Jerry Donovan; Christopher J Walkey; J Cliff Yoon; Francesco Oriente; Yukari Kitamura; Jennifer Altomonte; Hengjiang Dong; Domenico Accili; Bruce M Spiegelman
Journal:  Nature       Date:  2003-05-18       Impact factor: 49.962

10.  Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

Authors:  G G Holz; W M Kühtreiber; J F Habener
Journal:  Nature       Date:  1993-01-28       Impact factor: 49.962

View more
  7 in total

Review 1.  A synopsis of factors regulating beta cell development and beta cell mass.

Authors:  Krishna Prasadan; Chiyo Shiota; Xiao Xiangwei; David Ricks; Joseph Fusco; George Gittes
Journal:  Cell Mol Life Sci       Date:  2016-04-22       Impact factor: 9.261

Review 2.  Islet α cells and glucagon--critical regulators of energy homeostasis.

Authors:  Jonathan E Campbell; Daniel J Drucker
Journal:  Nat Rev Endocrinol       Date:  2015-04-07       Impact factor: 43.330

3.  Effects of genetics and in utero diet on murine pancreatic development.

Authors:  Chia-Lei Lin; Lyda Williams; Yoshinori Seki; Harpreet Kaur; Kirsten Hartil; Ariana Fiallo; A Scott Glenn; Ellen B Katz; Maureen J Charron; Patricia M Vuguin
Journal:  J Endocrinol       Date:  2014-06-03       Impact factor: 4.286

4.  Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor.

Authors:  Christine Longuet; Ana M Robledo; E Danielle Dean; Chunhua Dai; Safina Ali; Ian McGuinness; Vincent de Chavez; Patricia M Vuguin; Maureen J Charron; Alvin C Powers; Daniel J Drucker
Journal:  Diabetes       Date:  2012-11-16       Impact factor: 9.461

5.  Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides.

Authors:  Yuko Takano; Kenji Kasai; Yoshiko Takagishi; Toyone Kikumori; Tsuneo Imai; Yoshiharu Murata; Yoshitaka Hayashi
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

6.  Ectopic expression of GIP in pancreatic β-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides.

Authors:  Ayako Fukami; Yusuke Seino; Nobuaki Ozaki; Michiyo Yamamoto; Chisato Sugiyama; Eriko Sakamoto-Miura; Tatsuhito Himeno; Yoshiko Takagishi; Shin Tsunekawa; Safina Ali; Daniel J Drucker; Yoshiharu Murata; Yutaka Seino; Yutaka Oiso; Yoshitaka Hayashi
Journal:  Diabetes       Date:  2012-10-25       Impact factor: 9.461

Review 7.  Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.

Authors:  Daniel J Drucker
Journal:  Diabetes       Date:  2013-07-01       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.